LARIMAR THERAPEUTICS, INC. Research and Development Expense
LARIMAR THERAPEUTICS, INC. (LRMR) reported Research and Development Expense of $28.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $28.00M, a 19.82% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $25.03M, a 5.73% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $59.37M, a 122.05% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $44.93M, a 222.80% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. research and development expense for fiscal 2025 was $154.22M, a 110.46% increase from fiscal 2024.
- LARIMAR THERAPEUTICS, INC. research and development expense for fiscal 2024 was $73.28M, a 164.83% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. research and development expense for fiscal 2023 was $27.67M, a 14.10% increase from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. research and development expense for fiscal 2022 was $24.25M, a 36.84% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.00M 10-Q · filed 2026-08-04 | $53.03M 10-Q · filed 2026-08-04 | $112.40M derived: sum of 3 quarters · filed 2026-08-04 | $157.34M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $25.03M 10-Q · filed 2026-05-14 | $84.40M derived: sum of 2 quarters · filed 2026-05-14 | $129.34M derived: sum of 3 quarters · filed 2026-05-14 | $152.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $59.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $104.30M derived: sum of 2 quarters · filed 2026-03-19 | $127.67M derived: sum of 3 quarters · filed 2026-08-04 | $154.22M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $44.93M 10-Q · filed 2025-11-05 | $68.30M derived: sum of 2 quarters · filed 2026-08-04 | $94.85M 10-Q · filed 2025-11-05 | $121.59M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $23.37M 10-Q · filed 2026-08-04 | $49.92M 10-Q · filed 2026-08-04 | $76.66M derived: sum of 3 quarters · filed 2026-08-04 | $90.58M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $26.55M 10-Q · filed 2026-05-14 | $53.29M derived: sum of 2 quarters · filed 2026-05-14 | $67.21M derived: sum of 3 quarters · filed 2026-05-14 | $86.89M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $26.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $40.66M derived: sum of 2 quarters · filed 2026-03-19 | $60.34M derived: sum of 3 quarters · filed 2026-03-19 | $73.28M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $13.92M 10-Q · filed 2025-11-05 | $33.60M derived: sum of 2 quarters · filed 2025-11-05 | $46.54M 10-Q · filed 2025-11-05 | $57.19M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $19.68M 10-Q · filed 2025-08-14 | $32.62M 10-Q · filed 2025-08-14 | $43.27M derived: sum of 3 quarters · filed 2025-08-14 | $49.85M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $12.94M 10-Q · filed 2025-04-30 | $23.59M derived: sum of 2 quarters · filed 2025-04-30 | $30.17M derived: sum of 3 quarters · filed 2025-04-30 | $36.05M derived: sum of 4 quarters · filed 2025-04-30 | ||||
| 2023-12-31 | $10.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $17.23M derived: sum of 2 quarters · filed 2025-03-24 | $23.11M derived: sum of 3 quarters · filed 2025-03-24 | $27.67M 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | $6.58M 10-Q · filed 2024-10-30 | $12.46M derived: sum of 2 quarters · filed 2024-10-30 | $17.02M 10-Q · filed 2024-10-30 | $24.24M derived: sum of 4 quarters · filed 2024-10-30 | ||||
| 2023-06-30 | $5.88M 10-Q · filed 2024-08-08 | $10.44M 10-Q · filed 2024-08-08 | $17.66M derived: sum of 3 quarters · filed 2024-08-08 | $23.24M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $4.56M 10-Q · filed 2024-05-09 | $11.78M derived: sum of 2 quarters · filed 2024-05-09 | $17.36M derived: sum of 3 quarters · filed 2024-05-09 | $23.01M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $12.80M derived: sum of 2 quarters · filed 2024-03-14 | $18.44M derived: sum of 3 quarters · filed 2024-03-14 | $24.25M 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | $5.58M 10-Q · filed 2023-11-14 | $11.23M derived: sum of 2 quarters · filed 2023-11-14 | $17.03M 10-Q · filed 2023-11-14 | $23.32M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $5.64M 10-Q · filed 2023-08-10 | $11.45M 10-Q · filed 2023-08-10 | $17.74M derived: sum of 3 quarters · filed 2023-08-10 | $31.77M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $5.81M 10-Q · filed 2023-05-15 | $12.10M derived: sum of 2 quarters · filed 2023-05-15 | $26.13M derived: sum of 3 quarters · filed 2023-05-15 | $35.23M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $6.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $20.32M derived: sum of 2 quarters · filed 2023-03-14 | $29.42M derived: sum of 3 quarters · filed 2023-03-14 | $38.40M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $14.03M 10-Q · filed 2022-11-10 | $23.13M derived: sum of 2 quarters · filed 2022-11-10 | $32.10M 10-Q · filed 2022-11-10 | $42.68M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $9.10M 10-Q · filed 2022-08-11 | $18.08M 10-Q · filed 2022-08-11 | $28.65M derived: sum of 3 quarters · filed 2022-08-11 | $35.57M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $8.97M 10-Q · filed 2022-05-12 | $19.55M derived: sum of 2 quarters · filed 2022-05-12 | $26.47M derived: sum of 3 quarters · filed 2022-05-12 | $35.37M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $10.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $17.49M derived: sum of 2 quarters · filed 2022-03-25 | $26.40M derived: sum of 3 quarters · filed 2022-03-25 | $31.41M 10-K · filed 2022-03-25 | ||||
| 2020-09-30 | $6.92M 10-Q · filed 2021-11-12 | $15.83M derived: sum of 2 quarters · filed 2021-11-12 | $20.83M 10-Q · filed 2021-11-12 | $26.24M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $8.91M 10-Q · filed 2021-08-12 | $13.91M 10-Q · filed 2021-08-12 | $19.32M derived: sum of 3 quarters · filed 2021-08-12 | $27.35M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $5.01M 10-Q · filed 2021-05-10 | $10.41M derived: sum of 2 quarters · filed 2021-05-10 | $18.45M derived: sum of 3 quarters · filed 2021-05-10 | $21.57M derived: sum of 4 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | $5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $13.44M derived: sum of 2 quarters · filed 2021-03-04 | $16.57M derived: sum of 3 quarters · filed 2021-03-04 | $20.79M 10-K · filed 2021-03-04 | $23.89M 10-K · filed 2020-03-05 | |||
| 2019-09-30 | $8.03M 10-Q · filed 2020-11-12 | $5.26M 10-Q · filed 2019-11-06 | $11.16M derived: sum of 2 quarters · filed 2020-11-12 | $15.38M 10-Q · filed 2020-11-12 | $23.46M 10-Q · filed 2019-11-06 | $32.25M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $3.13M 10-Q · filed 2020-08-14 | $8.57M 10-Q · filed 2019-08-08 | $7.35M 10-Q · filed 2020-08-14 | $18.20M 10-Q · filed 2019-08-08 | $24.22M derived: sum of 3 quarters · filed 2020-08-14 | $36.05M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $9.63M 10-Q · filed 2019-05-09 | $21.09M derived: sum of 2 quarters · filed 2020-03-05 | $32.92M derived: sum of 3 quarters · filed 2020-03-05 | $45.13M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-12-31 | $11.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $23.29M derived: sum of 2 quarters · filed 2020-03-05 | $35.50M derived: sum of 3 quarters · filed 2020-03-05 | $47.93M 10-K · filed 2020-03-05 | ||||
| 2018-09-30 | $11.83M 10-Q · filed 2019-11-06 | $24.04M derived: sum of 2 quarters · filed 2019-11-06 | $36.47M 10-Q · filed 2019-11-06 | $47.38M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-06-30 | $12.21M 10-Q · filed 2019-08-08 | $24.64M 10-Q · filed 2019-08-08 | $35.55M derived: sum of 3 quarters · filed 2020-03-05 | $45.28M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-03-31 | $12.43M 10-Q · filed 2019-05-09 | $23.34M derived: sum of 2 quarters · filed 2020-03-05 | $33.07M derived: sum of 3 quarters · filed 2020-03-05 | $43.59M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2017-12-31 | $10.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $20.63M derived: sum of 2 quarters · filed 2020-03-05 | $31.16M derived: sum of 3 quarters · filed 2020-03-05 | $40.84M 10-K · filed 2020-03-05 | ||||
| 2017-09-30 | $9.72M 10-Q · filed 2018-11-09 | $20.25M derived: sum of 2 quarters · filed 2018-11-09 | $29.93M 10-Q · filed 2018-11-09 | $37.20M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-06-30 | $10.53M 10-Q · filed 2018-08-09 | $20.20M 10-Q · filed 2018-08-09 | $27.48M derived: sum of 3 quarters · filed 2019-03-14 | $37.48M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-03-31 | $9.68M 10-Q · filed 2018-05-10 | $16.95M derived: sum of 2 quarters · filed 2019-03-14 | $26.95M derived: sum of 3 quarters · filed 2019-03-14 | $37.12M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2016-12-31 | $7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $17.28M derived: sum of 2 quarters · filed 2019-03-14 | $27.44M derived: sum of 3 quarters · filed 2019-03-14 | $39.94M 10-K · filed 2019-03-14 | ||||
| 2016-09-30 | $10.00M 10-Q · filed 2017-11-07 | $20.16M derived: sum of 2 quarters · filed 2017-11-07 | $32.66M 10-Q · filed 2017-11-07 | $50.37M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2016-06-30 | $10.16M 10-Q · filed 2017-08-09 | $22.66M 10-Q · filed 2017-08-09 | $40.37M derived: sum of 3 quarters · filed 2018-03-09 | $54.54M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2016-03-31 | $12.50M 10-Q · filed 2017-05-09 | $30.20M derived: sum of 2 quarters · filed 2018-03-09 | $44.37M derived: sum of 3 quarters · filed 2018-03-09 | $56.90M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2015-12-31 | $17.71M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $31.88M derived: sum of 2 quarters · filed 2018-03-09 | $44.40M derived: sum of 3 quarters · filed 2018-03-09 | $54.62M 10-K · filed 2018-03-09 | ||||
| 2015-09-30 | $14.17M 10-Q · filed 2016-11-09 | $26.70M derived: sum of 2 quarters · filed 2016-11-09 | $36.91M 10-Q · filed 2016-11-09 | $44.26M derived: sum of 4 quarters · filed 2017-03-10 | ||||
| 2015-06-30 | $12.53M 10-Q · filed 2016-08-05 | $22.74M 10-Q · filed 2016-08-05 | $30.09M derived: sum of 3 quarters · filed 2017-03-10 | $42.16M derived: sum of 4 quarters · filed 2017-03-10 | ||||
| 2015-03-31 | $10.21M 10-Q · filed 2016-05-10 | $17.56M derived: sum of 2 quarters · filed 2017-03-10 | $29.64M derived: sum of 3 quarters · filed 2017-03-10 | $34.33M derived: sum of 4 quarters · filed 2017-03-10 | ||||
| 2014-12-31 | $7.34M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $19.42M derived: sum of 2 quarters · filed 2017-03-10 | $24.12M derived: sum of 3 quarters · filed 2017-03-10 | $27.39M 10-K · filed 2017-03-10 | ||||
| 2014-09-30 | $12.08M 10-Q · filed 2015-11-13 | $16.77M derived: sum of 2 quarters · filed 2015-08-14 | $20.05M 10-Q · filed 2015-11-13 | $22.57M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-06-30 | $4.70M 10-Q · filed 2015-08-14 | $7.97M 10-Q · filed 2015-08-14 | $10.49M derived: sum of 3 quarters · filed 2016-03-15 | $12.94M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | $3.27M 10-Q · filed 2015-05-14 | $5.80M derived: sum of 2 quarters · filed 2016-03-15 | $8.24M derived: sum of 3 quarters · filed 2016-03-15 | $10.20M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2013-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $4.97M derived: sum of 2 quarters · filed 2016-03-15 | $6.93M derived: sum of 3 quarters · filed 2016-03-15 | $9.56M 10-K · filed 2016-03-15 | ||||
| 2013-09-30 | $2.44M 10-Q · filed 2014-11-13 | $4.41M derived: sum of 2 quarters · filed 2014-11-13 | $7.04M 10-Q · filed 2014-11-13 | |||||
| 2013-06-30 | $1.96M 10-Q · filed 2014-08-14 | $4.59M 10-Q · filed 2014-08-14 | ||||||
| 2012-12-31 | $11.54M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |